



**Alberto Moriggia**

**Contact**

Alberto Moriggia

## Publications (4)

Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer M, Vernazza P, Scheidegger C. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort. *Swiss Med Wkly* 2021; 151:w20460.

Goossens N, Semela D, Razavi H, Negro F, Muellhaupt B, Moriggia A, Mertens J, Jornayvaz F, Dufour J, Cerny A, Bellentani S, Estes C. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. *Swiss Med Wkly* 2019; 149:w20152.

Bertisch B, Keiser O, Moradpour D, Zehnder C, Marinucci F, Roelens M, Moriggia A, Clerc O, Giudici F, Schmid P, Künzler-Heule P, Ottiger C, Mullhaupt B, Negro F, Brezzi M, Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?. *Clin Infect Dis* 2019

Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. *Int J Drug Policy* 2018; 62:94-103.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)